Monoclonal Antibodies
Monoclonal antibodies are laboratory-produced molecules designed to mimic the immune system’s natural antibodies. They work by attaching to specific cells, such as cancer cells, to help the immune system recognize and attack them.
Examples include Rituximab and Adcetris, which target specific antigens on cancer cells. By latching onto these antigens, the antibody tags the cancer cell for destruction by the immune system.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors work by blocking specific proteins that cancer cells use to evade the immune system. Two commonly targeted checkpoints are CTLA-4 and PD-1.
By preventing cancer cells from using these checkpoints, immune checkpoint inhibitors allow the immune system to recognize and attack cancerous cells more effectively. Key examples include Yervoy and Opdivo.
Clinical trials have demonstrated that these agents can significantly improve survival rates in various types of cancer. However, they are not without side effects, and monitoring for potential immune-related adverse events is crucial.
Vaccine Therapy
Cancer vaccine therapy is designed to stimulate a person’s own immune system to recognize and destroy cancer cells. It can be created using cancer cells, proteins from cancer cells, or genetic material from cancer cells.
Sipuleucel-T, a prostate cancer vaccine, is one example currently approved. It stimulates the immune system to attack prostate cancer cells by collecting the patient’s own immune cells, programming them to recognize and fight prostate cancer cells, and returning them to the body.
Peptide Vaccines
Peptide vaccines use synthetic versions of cancer proteins, or peptides, to prompt an immune response. These vaccines can be created to target specific proteins expressed by a particular type of cancer.
In clinical trials, peptide vaccines have demonstrated promising results in several cancers. A phase I/II clinical trial of a peptide vaccine for colorectal cancer, for example, showed that it could stimulate an immune response in 60% of patients.
Dendritic Cell Vaccines
Dendritic cell vaccines use specially engineered dendritic cells, which are key players in the immune system, to stimulate a more robust immune response. These vaccines can be created using the patient’s own tumor cells, which are processed and loaded onto dendritic cells to stimulate an immune response.
Clinical trials of dendritic cell vaccines are ongoing in various types of cancer, including lung, prostate, and breast cancer. Early results suggest that these vaccines may be effective in stimulating an immune response against cancer cells.
While cancer immunotherapy is promising, it is still a rapidly evolving field. Selection of appropriate immunotherapy, constant monitoring, and individualized treatment plans are crucial for successful outcomes.